Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacia Corp. a future biotech powerhouse? -- Ignore unavailable to you. Want to Upgrade?

To: Cheeseburger who wrote (26)	9/26/2000 12:24:28 PM
From: SteveR	Read Replies (1) \| Respond to of 35

Don't know about that, but the following is from one of their recent press releases: ZYVOX is generally well tolerated. The adverse events reported for patients receiving ZYVOX and comparators in clinical trials were similar. The most common events for patients treated with ZYVOX were diarrhea (8.3 percent), headache (6.5 percent), nausea (6.2 percent) and vomiting (3.7 percent). Events were usually mild to moderate in intensity and limited in duration. Certain patients should have periodic monitoring of their blood platelet levels while taking ZYVOX. 'Regards... SteveR